EMD Serono
PharmaDarmstadt, Germany, Germany · Est. 1846
EMD Serono is a biopharmaceutical company specializing in innovative therapies for oncology, fertility, and neurological disorders.
0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
78
Clinical Trials↗
All sponsored trials (all statuses)
12
Orange Book Patents
Across 3 drugs with upcoming expirations
Activity
Key Events
Aug 31, 2026FDABavencio — BAVENCIO
Aug 27, 2026TrialA Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Jul 9, 2025FDAGenotropin — GENOTROPIN PRESERVATIVE FREE, GENOTROPIN
Jun 4, 2025FDABavencio — BAVENCIO
Nov 26, 2024FDABavencio — BAVENCIO
Oct 11, 2024FDABavencio — BAVENCIO
Aug 16, 2024FDAGenotropin — GENOTROPIN PRESERVATIVE FREE, GENOTROPIN
Mar 6, 2024FDABavencio — BAVENCIO
1 more events
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
OncologyFertilityNeurodegenerative DiseasesImmunology
Regulatory
Regulatory Timeline
20194 events
FDAAug 29
Glucophage — RIOMET ER
Application NDA212595 (NDA)
FDAAug 29
Riomet Er — RIOMET ER
Application NDA212595 (NDA)
FDAAug 29
Glucophage — RIOMET ER
Application NDA212595 (NDA)
FDAMay 14
Bavencio — BAVENCIO
Application BLA761049
20203 events
FDANov 10
Bavencio — BAVENCIO
Application BLA761049
FDAJun 30
Bavencio — BAVENCIO
Application BLA761049
FDAJan 8
Genotropin — GENOTROPIN PRESERVATIVE FREE, GENOTROPIN
Application BLA020280
20211 event
FDAFeb 3
Tepmetko — TEPMETKO
Application NDA214096 (NDA)
20221 event
FDAJul 15
Bavencio — BAVENCIO
Application BLA761049
20233 events
FDASep 6
Bavencio — BAVENCIO
Application BLA761049
FDAMar 23
Tepmetko — TEPMETKO
Application NDA214096
FDAMar 23
Tepmetko — TEPMETKO
Application NDA214096
20245 events
FDANov 26
Bavencio — BAVENCIO
Application BLA761049
FDAOct 11
Bavencio — BAVENCIO
Application BLA761049
FDAAug 16
Genotropin — GENOTROPIN PRESERVATIVE FREE, GENOTROPIN
Application BLA020280
FDAMar 6
Bavencio — BAVENCIO
Application BLA761049
FDAFeb 15
Tepmetko — TEPMETKO
Application NDA214096
20252 events
FDAJul 9
Genotropin — GENOTROPIN PRESERVATIVE FREE, GENOTROPIN
Application BLA020280
FDAJun 4
Bavencio — BAVENCIO
Application BLA761049
20261 event
FDAAug 31
Bavencio — BAVENCIO
Application BLA761049
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)